ReviewHuman vaccines & immunotherapeutics2024
Immunotherapy and delivery systems for melanoma.
Review in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Delivery Strategies for Oncolytic Viruses in Gastrointestinal Cancers: Progress, Mechanisms and Clinical Translations.Reviews in medical virology · 2026Review
- Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2026Review
- Nanosized Cerium Phosphate: Synthesis Methods, Morphology, and Potential Applications in Biomedicine.Biomedicines · 2026Review
- GSH-Responsive PBAE Polymers for IL-12 mRNA Delivery in Melanoma Immunotherapy.Investigative ophthalmology & visual science · 2026Article
- Hydrogel-based delivery systems for cutaneous melanoma therapy: from chemical design and crosslinking strategies to structure-activity relationships.RSC advances · 2026Review
- Applications of Antioxidant Nanoparticles, 2nd Edition.Antioxidants (Basel, Switzerland) · 2026Article
- Nanoparticle-Modified Nanofibers Induce Ferroptosis and Stimulate Antitumor Immunity for Melanoma Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Peptide hydrogel boosts the cytotoxic and metabolic fitness of Vγ9Vδ2 T cells in melanoma immunotherapy.Frontiers in immunology · 2026Article
- [Immunotherapy of cutaneous neoplasms].Magyar onkologia · 2025Review
- Fyn inhibition by TAE684: A synergistic strategy to suppress melanoma and reverse vemurafenib resistance.Cell death & disease · 2025Article
- Article
- Adjuvant Immunotherapy in Stage IIB/IIC Melanoma: Current Evidence and Future Directions.Biomedicines · 2025Review
- Genetic Landscape of Familial Melanoma.Genes · 2025Review
- Nanomaterials for targeted drug delivery for immunotherapy of digestive tract tumors.Frontiers in immunology · 2025Review
- Stimuli-Responsive Drug Delivery Systems for Enhanced Melanoma Immunotherapy.Drug design, development and therapy · 2025Review
- Case Report: An unexpected case of tumor regression in blue nevus melanoma following COVID-19 infection.Frontiers in immunology · 2025Article
- Bioinformatics-based prognostic value andFrontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma is a highly malignant tumor of melanocyte origin that is prone to early metastasis and has a very poor prognosis. Early melanoma treatment modalities are mainly surgical, and treatment strategies for advanced or metastatic melanoma contain chemotherapy, radiotherapy, targeted therapy and immunotherapy. The efficacy of chemotherapy and radiotherapy has been unsatisfactory due to low sensitivity and strong toxic side effects. And targeted therapy is prone to drug resistance, so its clinical application is limited. Melanoma has always been the leader of immunotherapy for solid tumors, and how to maximize the role of immunotherapy and how to implement immunotherapy more accurately are still urgent to be explored. This review summarizes the common immunotherapies and applications for melanoma, illustrates the current research status of melanoma immunotherapy delivery systems, and discusses the advantages and disadvantages of each delivery system and its prospects for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.